896 related articles for article (PubMed ID: 23604429)
1. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease.
Großekatthöfer M; Güclü ED; Lawitschka A; Matthes-Martin S; Mann G; Minkov M; Peters C; Seidel MG
Ann Hematol; 2013 Aug; 92(8):1121-8. PubMed ID: 23604429
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Ferritin as an early marker of graft rejection after allogeneic hematopoietic stem cell transplantation in pediatric patients.
Döring M; Cabanillas Stanchi KM; Feucht J; Queudeville M; Teltschik HM; Lang P; Feuchtinger T; Handgretinger R; Müller I
Ann Hematol; 2016 Jan; 95(2):311-23. PubMed ID: 26611853
[TBL] [Abstract][Full Text] [Related]
4. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
[TBL] [Abstract][Full Text] [Related]
5. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
6. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Kamble RT; Selby GB; Mims M; Kharfan-Dabaja MA; Ozer H; George JN
Biol Blood Marrow Transplant; 2006 May; 12(5):506-10. PubMed ID: 16635785
[TBL] [Abstract][Full Text] [Related]
7. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.
Busca A; Falda M; Manzini P; D'Antico S; Valfrè A; Locatelli F; Calabrese R; Chiappella A; D'Ardia S; Longo F; Piga A
Biol Blood Marrow Transplant; 2010 Jan; 16(1):115-22. PubMed ID: 19766730
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children.
Mochizuki K; Kikuta A; Ito M; Sano H; Akaihata M; Kobayashi S; Ohto H; Hosoya M
Clin Transplant; 2011; 25(6):892-7. PubMed ID: 21070366
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing outcome and incidence of late complications in children who underwent allogeneic hematopoietic stem cell transplantation for hemoglobinopathy.
Khalil A; Zaidman I; Elhasid R; Peretz-Nahum M; Futerman B; Ben-Arush M
Pediatr Hematol Oncol; 2012 Nov; 29(8):694-703. PubMed ID: 23020512
[TBL] [Abstract][Full Text] [Related]
10. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
11. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Avanzini MA; Maccario R; Locatelli F; Giebel S; Santos CD; Bernardo ME; Pagliara D; Montagna D; Longo S; Amendola G; Marconi M
Exp Hematol; 2006 Oct; 34(10):1429-34. PubMed ID: 16982336
[TBL] [Abstract][Full Text] [Related]
12. Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation.
Sucak GT; Yegin ZA; Ozkurt ZN; Aki SZ; Yağci M
Transplant Proc; 2010 Jun; 42(5):1841-8. PubMed ID: 20620535
[TBL] [Abstract][Full Text] [Related]
13. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
14. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
15. Vitamin d levels affect outcome in pediatric hematopoietic stem cell transplantation.
Hansson ME; Norlin AC; Omazic B; Wikström AC; Bergman P; Winiarski J; Remberger M; Sundin M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1537-43. PubMed ID: 24910378
[TBL] [Abstract][Full Text] [Related]
16. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
[TBL] [Abstract][Full Text] [Related]
17. Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation.
McNeer JL; Kletzel M; Rademaker A; Alford K; O'Day K; Schaefer C; Duerst R; Jacobsohn DA
Biol Blood Marrow Transplant; 2010 Mar; 16(3):350-7. PubMed ID: 20005964
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
Yeh AC; Brunner AM; Spitzer TR; Chen YB; Coughlin E; McAfee S; Ballen K; Attar E; Caron M; Preffer FI; Yeap BY; Dey BR
Biol Blood Marrow Transplant; 2014 May; 20(5):730-4. PubMed ID: 24530972
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
20. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
